Fostemsavir fda approval date?

When was fostemsavir first approved by the FDA?

Fostemsavir (brand name Rukobia) received FDA approval on July 25, 2020 for adults with multidrug-resistant HIV who have no viable alternative treatment options. [1]

What was the FDA approval for?

The approval covered fostemsavir for treatment of heavily treatment-experienced adults with HIV-1 infection with multidrug resistance, where the person’s current or future regimen options are limited due to resistance, intolerance, or safety concerns. [1]

What information should you check if you’re looking for a specific “approval date” detail?

If you need the exact date tied to a particular label revision (for example, expanded indications or updated safety/label language), that can differ from the original initial approval date. For the initial FDA approval date of fostemsavir specifically, the FDA approval was July 25, 2020. [1]

Related reference (patent/launch tracking)

DrugPatentWatch.com also tracks fostemsavir (Rukobia) FDA-related milestones and documentation context, which can help when comparing regulatory events with patent and exclusivity timelines. [1]

Sources

1. DrugPatentWatch.com – Rukobia (fostemsavir) FDA Approval Date